Cumberland Pharmaceuticals Inc
$ 7.80
1.56%
07 Aug - close price
- Market Cap 116,868,000 USD
- Current Price $ 7.80
- High / Low $ 7.99 / 7.55
- Stock P/E N/A
- Book Value 1.16
- EPS -0.63
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.14 %
- 52 Week High 8.23
- 52 Week Low 1.13
About
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and marketing of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company is headquartered in Nashville, Tennessee.
Analyst Target Price
$8.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-03-03 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-04 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-07 |
| Reported EPS | -0.2 | -0.2199 | -0.0944 | -0.1297 | -0.05 | 0.0824 | -0.1363 | -0.1099 | -0.0769 | -0.1381 | -0.4441 | 0.02 |
| Estimated EPS | None | 0 | 0 | 0 | 0 | None | None | None | None | None | None | None |
| Surprise | 0 | -0.2199 | -0.0944 | -0.1297 | -0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | |
|---|---|
| Payment Date | 2026-07-31 |
| Amount | $1.5 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CPIX
2026-08-06 07:12:30
Cumberland Pharmaceuticals (CPIX) stock declined by 2.8% today, despite a significant strategic pivot. The company recently completed a $100 million divestiture and issued a $1.50 per share special dividend, transforming it into a cash-rich, development-focused biotech. While Q2 2026 showed operating and net losses, the new focus is on balance sheet strength and clinical execution of its ifetroban programs, with management projecting over five years of financial runway.
2026-08-05 14:39:26
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a quarterly loss of $0.20 per share, missing analyst estimates. The company closed its Apotex transaction for $100 million and declared a special dividend of $1.50 per share, pivoting to focus on its ifetroban development pipeline. Despite the strategic shift to a development-stage biopharmaceutical company, analysts maintain a "Sell" rating on the stock.
2026-08-05 04:12:49
Cumberland Pharmaceuticals announced a strategic shift in Q2 2026, selling its commercial brands to Apotex Health to transition into a biopharmaceutical development company. This transaction significantly strengthened its balance sheet with $100 million at closing and an estimated $108 million in total net proceeds, allowing it to fund operations for over five years and focus on its ifetroban clinical programs for various serious diseases. Despite a reported net loss of $4.1 million for the quarter, shares saw initial gains followed by an after-hours dip, as investors assessed the long-term potential of its new development-focused model.
2026-08-04 21:25:00
Cumberland Pharmaceuticals (CPIX) reported a net loss of $4.1 million and net revenues of $166,458 for the second quarter of 2026, leading to a $0.27 loss per share. This follows a strategic transaction where Apotex Health acquired Cumberland’s FDA-approved brand portfolio for $100 million in cash, prompting Cumberland to declare a special cash dividend of $1.50 per share. Despite the loss, Cumberland retains late-stage development candidates, including four Phase 2 clinical programs.
2026-08-04 21:12:49
Cumberland Pharmaceuticals announced its Q2 2026 financial results and the completion of a $100 million strategic transaction with Apotex Health, involving the sale of its FDA-approved brands. Following this deal, Cumberland is transitioning to a development-stage biopharmaceutical company and has declared a special cash dividend of $1.50 per share to its shareholders. The company also reported Q2 2026 net loss of $4.1 million and presented updated positive Phase 2 clinical trial results for ifetroban in Duchenne muscular dystrophy and cancer metastasis prevention.
2026-08-01 03:41:47
This article lists ETFs that hold Cumberland Pharmaceuticals Inc. (CPIX) stocks, providing investors with options for more accessible and lower-risk investment opportunities. It highlights one specific ETF, the Bridgeway Ultra-Small Company Market ETF (BUSM), detailing its market value, weight in CPIX, management style, and expense ratio. The article serves as a resource for investors interested in diversified exposure to Cumberland Pharmaceuticals.
